Background: The peritoneal fluid (PF) of women with endometriosis contains protease(s) activity able to hydrolyze insulin-like growth factor-binding protein 3 (IGFBP-3), increasing the bioavailability of insulin-like growth factor-1 (IGF-1) locally. Therefore, we characterized the effects of IGF-1 on KLE endometrial-like cells in vitro.
Introduction
Endometriosis is defined as the ectopic growth of endometrial-like tissue on the peritoneum and the organs of the pelvic cavity (1) . The pathogenesis of endometriosis may be associated with the phenomenon of retrograde menstruation; whereas, the ectopic growth of endometrial-like tissue is dependent upon sex steroid hormones and local growth factors, such as insulin-like growth factor 1 (IGF-1) (2, 3) .
Recent studies documented that peritoneal fluid (PF) of women with and without laparoscopic evidence of endometriosis contained growth factor activity for endometrial-like cells, which is, at least in part, associated with the production of N-terminal proteolytic fragments of IGF-binding protein 3 (IGFBP-3) (4, 5) . These N-terminal truncated forms of IGFBP-3 contained significant mitogenic activity for endometrial-like cells in vitro (5) . In addition, when the PF of women with endometriosis were analyzed by isoelectric focusing, the N-terminal truncated forms of IGFBP-3 co-eluted with urokinase-type plasminogen activator (uPA), a serine protease capable of hydrolyzing IGFBP-3, thereby, increasing IGF-1 bioavailability locally (6) .
Notably, uPA is known to have a pivotal role in regulating the activity of other matrix proteases (7, 8) and several growth substances, such as the IGFs in the extracellular matrix, circulation, and other body fluids, including PF (9) (10) (11) (12) (13) . Recently, our laboratory documented that the exogenous administration of IGF-1 and endogenous increase of IGF-1 bioavailability produced by the uPA-mediated-limited hydrolysis of IGFBPs, rescued breast and prostate cancer cells from programmed cell death in vitro (14) (15) (16) . In addition, anti-IGF-1 therapy reintroduced an objective clinical response to androgen ablation therapy of prostate cancer patients who had progressed to the hormone refractory stage of the disease (17) . These data indicated that exogenous IGF-1 and/or endogenously increased IGF-1 bioavailability in host tissues can exert a novel survival factor activity, rescuing metastatic cancer cells from apoptosis in vitro (18) .
Since the pathophysiology of endometriosis may include the transplantation of endometrial-like cells in the peritoneal cavity, it is conceivable that a survival mechanism could participate in the pathogenesis of endometriosis (19) . This survival mechanism could enable endometrial-like cells, reaching the peritoneal cavity by retrograde menstruation, first to survive, and then to grow and develop the endometriotic tissue on the peritoneum and the organs of peritoneal cavity (20) .
Therefore, we assessed whether exogenous IGF-1, apart from being a growth factor, can optimize the survival of KLE endometrial-like cells in vitro. Indeed, IGF-1 stimulated the growth and protected KLE endometrial-like cells from adriamycin-apoptosis in vitro. Therefore, it is possible that an increased IGF-1 activity in the PF of women with endometriosis can optimize both the survival and growth of ectopic endometrial-like tissue.
Material and Methods

Cell Cultures
KLE endometrial-like cells were characterized in our laboratory previously when we studied their response to growth factors (including IGF-I) and peritoneal fluid mitogens in parallel experiments using the primary cultures of epithelial cells enzymatically prepared from biopsies of endometrial tissue and endometriotic lesions as control (4, 5) . KLE cells were grown in 75-cm 2 culture flasks using Dulbecco's modified Eagle's medium/F-12 (DMEM/F-12, GIBCO/ BRL, Gaithersburg, MD) containing 5% calf serum (CS). The KLE cells were plated at a cell density of 15,000 cells in 24-well plates and grown for 48 hr with DMEM/F-12 medium containing 0.5-5% CS, depending on the experiment. After 48 hr incubation, the culture media were changed with media containing 5% CS and increasing concentrations (1-100 ng/ml) of recombinant human IGF-1 (R&D Systems) or two different concentrations (100 nM and 5 M) of adriamycin (Sigma) were added. In addition, experiments assessing the combined effect of adriamycin (100 nM) plus IGF-1 (50 ng/ml) were performed.
Cytotoxicity Assays
The number of alive and dead KLE cells was assessed by trypan blue exclusion after their exposure to 100 nM and 5 M adriamycin for 48 hr. The KLE cells were plated at 15,000 cells/well and cultured with media supplemented with 0.5%, 2.5%, and 5% CS plus 100 nM or 5M of adriamycin. The ratio of alive vs. dead cells was computed (A/D ratio) and compared with that of adriamycin-free cultures as described previously (14, 15) .
Apoptosis on Simple Agarose Gel
Apoptosis was assessed by the detection of DNA fragments (DNA ladders of multiples of 180 base pairs; bp) on simple agarose gel electrophoresis of total cellular DNA, as described previously (14, 15) .
Flow Cytometry
The indexes of KLE cell cycle and apoptosis were assessed by flow cytometry analyzing DNA content in propidium iodide and HOECHST 33342-stained cells with a counter EPICS 753 pulse cytometer (Coulter Counter, Hialeah, FL). This technique permitted the calculation of the apoptotic cells, excluding necrotic cells (21). The KLE cells were exposed to 100 nM of adriamycin for 48 hr. We analyzed apoptosis (% of DNA content ϽG1) and computed the percentage of apoptotic cells and percent of phase distribution of KLE cells into the cell cycle, as described previously (14, 15) .
IGF-I Effects on KLE Cell Growth and Protection from Adriamycin Apoptosis
We analyzed the ability of the optimal dose of IGF-I (50 ng/mL) to protect KLE cells from adriamycin cytotoxicity. This was by calculating the number of dead (D) and alive (A) KLE cells, and by computing the A/D ratio using trypan blue exclusion. In addition, we analyzed the percent distribution of KLE cells at ϽGl, G1/G0, S, G2/M phases in the cell cycle using flow cytometry. The optimal dose of IGF-1 was calculated by analyzing the dose-dependent effects of IGF-1 (1-100 ng/ml, final concentration) on the expected number and DNA content of KLE cells in vitro (14) (15) (16) .
Statistical Analysis
The group means were assessed for statistical significance using one-tailed multiple comparison procedure of Dunnett's test only when treatments were compared with control values. When single comparisons were made, Student's test was used.
Results
IGF-1 Effects on the Proliferation of KLE Cells
IGF-1 produced a dose-dependent effect on the growth of KLE cells, as documented by the increasing number of alive KLE cells and increasing DNA content in KLE cell cultures (Fig. 1) . The optimal dose of IGF-1 was 50 ng/ml, which was capable of increasing by 35% the expected DNA content and number of KLE cells (p Ͻ 0.001). The expected DNA content and expected number of KLE cells were determined by parallel experiments in IGF-free cultures (controls) under identical experimental conditions. These data documented that IGF-1 exerted important mitogenic activity on KLE endometriallike cells.
Adriamycin Cytotoxicity of KLE Cells by Trypan Blue
The 48-hr exposure of KLE cells to 100 nM (pharmacological dose) and 5 M (suprapharmacological dose) of adriamycin remarkably decreased (p Ͻ 0.001) the expected number of alive KLE cells grown with 0.5%, 2.5%, and 5% CS (Fig. 2) . The expected number of KLE cells was determined by parallel experiments in adriamycin-free cultures (controls).
Analysis of KLE Cell Cycle and Adriamycin Apoptosis by Flow Cytometry
The phase distribution of KLE cells in the cell cycle and very few apoptotic (ϽG1 ϭ 1%) were documented by flow cytometry in adriamycin-free KLE cultures (Fig. 3) . However, exposure to adriamycin (100 nM for 48 hr) produced a remarkable growth arrest of the KLE cells at G2/M phase, as suggested by the percent distribution of KLE cells in the cell cycle, which increased from 9.5% to 74.5%. This was produced at the expenses of the percent distribution of KLE cells at G1/G0 and S phases, which decreased from 55.5% to 10%, and from 35% to 15.5%, respectively (Fig. 3) . Moreover, adriamycin produced clear evidence of apoptosis (DNA fragmentation) of KLE cells, increasing the percent distribution at ϽG1 from 1% to 29.5%
In addition, 2.5% and 5.0% CS remarkably increased (p Ͻ 0.001) the expected number of alive KLE cells, compared with KLE cultures containing 0.5% CS. Apparently, 5% CS provided maximum stimulation for the growth of KLE cells in vitro (Fig. 2) . Consequently, all future experiments were uniformly performed in DMEM/F-12 media containing 5.0% CS. Increasing the concentration of CS did not modify the effects of 100 nM and those of 5 M of adriamycin on the number of alive KLE cells (Fig. 2) .
The expected number of dead KLE cells was increased significantly (p Ͻ 0.001) after 48-hr exposure to pharmacological (100 nM) and suprapharmacological doses (5 M) of adriamycin, as was calculated with trypan blue exclusion (Fig. 2) . Because the analysis of adriamycin cytotoxicity must always consider the number of alive vs. dead cells in each cell culture (cytostasis probably decreases cytotoxicity), we also expressed our data as ratio of alive ( Fig. 3) . Most of the KLE cells exposed to 5 M of adriamycin for 48 hr underwent apoptosis (75.0 Ϯ 5.0% of cells at ϽG1); whereas, the remaining few KLE cells in the cell cycle were distributed at the G1/G0 and S phase and a few KLE cells were found at G2/M phase (data not shown). Adriamycin (100 nM) induced the apoptosis of KLE cells, as noted by the increased percent distribution of KLE cells at ϽG1 phase in the cell cycle, from 1.5% Ϯ 1 of controls to 29.5 Ϯ 1.5% of adriamycin-treated KLE cells. In addition, adriamycin remarkably increased the percent distribution of KLE cells in the G2/M phase at the expenses of G1/G2 and S phases (G2/M phase increased from 9.5% Ϯ 2.2 of controls to 74.5% Ϯ 3.0 of adriamycin-treated KLE cells; whereas, G1/G0 phase decreased from 55.5% Ϯ 3.0 of controls to 10% Ϯ 2.0 in adriamycintreated KLE cells and S phase decreased from 35% Ϯ 1.5 in controls to 15.5% Ϯ 2.2 of adriamycin-treated KLE cells (p Ͻ 0.001). Therefore, adriamycin arrested KLE cells at G2/M phase and induced apoptosis of KLE cells. IGF-1 (50 ng/ml) decreased percent distribution at G2/M phase by 50% and percent distribution at ϽG1 phase by 38% of adriamycintreated KLE cells (p Ͻ 0.001). 
Analysis of DNA on Simple Agarose Gel
Adriamycin (100 nM) apoptosis of KLE cells also was confirmed by the analysis of DNA on simple agarose gel, detecting the classic DNA ladders (multiple of 180 bp fragments) that accompanied programmed cell death in vitro (Fig. 4) .
IGF-1 Inhibition of Adriamycin Cytotoxicity
The optimal dose of IGF-1 as a growth factor on KLE cells (50 ng/ml) partially reversed the adriamycin (100 nM) effects on the cell cycle of KLE cells (Fig. 3) . In addition, the optimal mitogenic dose of IGF-1 (50 ng/ml) partially protected KLE cells from adriamycin apoptosis (Fig. 3) . Therefore, IGF-1 reversed both the adriamycin-induced cytostasis and adriamycin-induced apoptosis of KLE cells.
In concert with the above data, the optimal mitogenic dose (50 ng/ml) of IGF-1 also partially reversed the effects of adriamycin on the number of alive and dead KLE cells (Fig. 5 ). In addition, the A/D ratio of KLE cells increased from 2.4 (adriamycin 100 nM) to 31.0 (adriamycin plus IGF-1). Therefore, IGF-1 was a survival factor protecting KLE cells from adriamycin cytostasis and apoptosis.
Discussion
Regardless of which theory is the correct one for the pathogenesis of endometriosis: celomic metaplasia hypothesis, transplantation theory, or induction hypothesis (1,2), development and evolution/progres-researchers have implicated the uPA/plasmin system and other matrix proteases in the pathophysiology of several reproductive tissues, including endometrium (38) (39) (40) .
Because the pathogenesis of endometriosis possibly implicates the ectopic growth of endometriallike cells in the peritoneal cavity and it recently was reported that ectopic endometrial-like tissue presented with possible evidence of an altered apoptosis (41-44), we assessed whether an increased IGF-1 activity can protect endometrial-like cells from apoptosis. KLE is an endometrial cancer-derived cells that shares some characteristics of endometriallike cells (4, 45) . Our study of the possible role of IGF-1 as survival factor on KLE cells was proceeded by the characterization of adriamycin cytotoxicity of KLE cells. Under our experimental conditions, adriamycin (100 nM for 48 hr) produced the apoptosis of KLE endometrial-like cells and effectively arrested KLE cells at the G2/M phase in the cell cycle. Adriamycin cytotoxicity of KLE cells was neutralized partially by the exogenous IGF-1.
These data were in concert with recent findings that the exogenous administration of IGF-1 rescued breast and prostate cancer cells from programmed cell death in vitro (14, 15) . Other, studies suggest that endogenous interleukin-6, which is known to be increased in the PF of women with endometriosis (29) , is also a resistance factor for etoposide-mediated cytotoxicity of prostate cancer cells; whereas, IGF-1 is a survival factor for PC-12 cells (46, 47) . The growth factor-mediated mechanism(s) of this rescue from apoptosis is unknown.
Recently, IGF-1 inhibition of the apoptosis of PC-12 cells was associated with an increased expression of the bcl-xL gene product, suggesting that growth factors can regulate apoptosis-related genes acting as transcription factors (47) . In addition, particular checkpoints were detected in apoptosis molecular pathways that met with the growth factor-signal transduction pathways (48) . These checkpoints implicated serine phosphorylation-elimination of a death agonist Bad gene product as part of the response to survival factors (48, 49) . Whether a similar mechanism is associated with the action of the IGF-1 as "survival factors" on endometrial-like cells is currently under investigation in our laboratory.
In conclusion, several factors already have been characterized in the PF of women suffering from endometriosis for their mitogenic, angiogenic and immunosuppressive activity on endometrial-like cells. Our data suggest that the same autocrine/paracrine modulators of PF also may be implicated in optimizing the survival of endometrial-like cells in the peritoneal cavity. Herein, we document the role of IGF-1 as an important survival factor for endometrial-like cells in vitro. Conceivably, if these data hold to the in vivo situation, the protease(s)-mediated increase in IGF-1 activity can act similar to the survival growth factor for endometrial-like cells in the perision of this disease is almost certainly associated with an abnormal immune function, altered peritoneal defense system, and bioactivity of growth substances in the endometrial-like tissue and PF (3, 22, 23) .
It currently is accepted that endometriosis is an entity of extreme pleiomorphism, which may include various and, in cases, overlapping pathogenetic pathways, including enviromental toxins (22) (23) (24) (25) (26) . In addition, several growth substances of PF have been associated with the presence and severity of expression of endometriosis, including the uPA/IGFs/ IGFBP-3 bioregulation system, interleukins (ILs), transforming growth factor ␤ 1 (TGF␤1), tumor necrosis factor ␣ (TNF␣), and vascular-endothelial growth factor (VEGF) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) .
Regarding the role of growth factors in the PF of women with endometriosis, particular interest has focused on the uPA-mediated production of N-terminal proteolytic fragments of IGFBP-3 (3,5,6,10). Our laboratory also placed a lot of attention on the possible pivotal role of uPA in regulating the activity of several growth substances, such as the IGFs, in cancer metastases (7, 9, 18) and PF (4) (5) (6) . In addition, other toneal cavity of women with endometriosis. The later may suggest that pharmacologically targeting the survival factor activity of PF and endometriallike tissue can provide a novel therapeutic approach for the management of endometriosis.
